Company / SG&A Expense
Acadia Pharmaceuticals SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$548.9M
FY2025
5-year range
$369.1M / $548.9M
FY2021-FY2025
Trend
+12.4%
vs FY2024
Sector context
#34 of 213
Health Care
What the data says
Acadia Pharmaceuticals's sg&a expense of $549M is higher than 84% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 3 consecutive years, from $369M in FY2022 to $549M in FY2025.
Based on SEC 10-K filings.
$549M in FY2025 with a 5-year CAGR of +7.1%. Top quartile in the Health Care sector.
Increased from $407M to $549M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +14.1%
- 5-Year CAGR
- +7.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 213This company $548.9M Sector average $722.3M
▼
-24.0% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +7.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 12.4% year-over-year.
- Ranks #34 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $548.9M | +12.4% |
| FY2024 | $488.4M | +20.1% |
| FY2023 | $406.6M | +10.2% |
| FY2022 | $369.1M | -6.8% |
| FY2021 | $396.0M | +1.9% |
| FY2020 | $388.7M | +19.4% |
| FY2019 | $325.6M | +22.5% |
| FY2018 | $265.8M | +4.2% |
| FY2017 | $255.1M | +36.8% |
| FY2016 | $186.5M | +111.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026